Cargando…

Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate

Prostate biopsy is recommended in cases of positive magnetic resonance imaging (MRI), defined as Prostate Imaging Reporting and Data System (PIRADS) category ≥ 3. However, most men with positive MRIs will not be diagnosed with clinically significant prostate cancer (csPC). Our goal was to evaluate p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szempliński, Stanisław, Kamecki, Hubert, Dębowska, Małgorzata, Zagożdżon, Bartłomiej, Mokrzyś, Mateusz, Zawadzki, Marek, Sosnowski, Roman, Tokarczyk, Andrzej, Poletajew, Sławomir, Kryst, Piotr, Nyk, Łukasz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820960/ https://www.ncbi.nlm.nih.gov/pubmed/36614957 http://dx.doi.org/10.3390/jcm12010156

Ejemplares similares

Patient-reported pain associated with grid-based transperineal magnetic resonance imaging (MRI)/ultrasound (US) software fusion biopsy of the prostate under local anesthesia: a multicenter experience
por: Szempliński, Stanisław, et al.
Publicado: (2023)

The Impact of the Ongoing COVID-19 Epidemic on the Increasing Risk of Adverse Pathology in Prostate Cancer Patients Undergoing Radical Prostatectomy
por: Nyk, Łukasz, et al.
Publicado: (2022)

Prostate Biopsy in the Case of PIRADS 5—Is Systematic Biopsy Mandatory?
por: Malewski, Wojciech, et al.
Publicado: (2023)

High-Intensity Focused-Ultrasound Focal Therapy Versus Laparoscopic Radical Prostatectomy: A Comparison of Oncological and Functional Outcomes in Low- and Intermediate-Risk Prostate Cancer Patients
por: Nyk, Łukasz, et al.
Publicado: (2022)

Quantification of Gleason Pattern 4 at MRI-Guided Biopsy to Predict Adverse Pathology at Radical Prostatectomy in Intermediate-Risk Prostate Cancer Patients
por: Kamecki, Hubert, et al.
Publicado: (2023)

Diagnostic Performance of Preoperative Choline-PET/CT in Patients Undergoing Salvage Lymph Node Dissection for Recurrent Prostate Cancer: A Multicenter Experience
por: Nyk, Łukasz, et al.
Publicado: (2022)

The molecular mechanisms of fluoroquinolone resistance found in rectal swab isolates of Enterobacterales from men undergoing a transrectal prostate biopsy: the rationale for targeted prophylaxis
por: Piekarska, Katarzyna, et al.
Publicado: (2021)

Incidental Diagnosis of Urothelial Bladder Cancer: Associations with Overall Survival
por: Kamecki, Hubert, et al.
Publicado: (2023)

The role of mpMRI in qualification of patients with ISUP 1 prostate cancer on biopsy to radical prostatectomy
por: Nyk, Łukasz, et al.
Publicado: (2021)

New Diagnostic Model for Clinically Significant Prostate Cancer in Biopsy-Naïve Men With PIRADS 3
por: Huang, Chen, et al.
Publicado: (2022)

Should all specimens taken during surgical treatment of patients with benign prostatic hyperplasia be assessed by a pathologist?
por: Skrzypczyk, Michał Andrzej, et al.
Publicado: (2014)

Active surveillance for low-risk prostate cancer: well established, yet avoided?
por: Sosnowski, Roman, et al.
Publicado: (2022)

Multi-Drug Resistant Bacteria as Aetiological Factors of Infections in a Tertiary Multidisciplinary Hospital in Poland
por: Poletajew, Sławomir, et al.
Publicado: (2021)

New model of PIRADS and adjusted prostate-specific antigen density of peripheral zone improves the detection rate of initial prostate biopsy: a diagnostic study
por: Huang, Chen, et al.
Publicado: (2022)

Prediction of prostate cancer Gleason score upgrading from biopsy to radical prostatectomy using pre-biopsy multiparametric MRI PIRADS scoring system
por: Alqahtani, Saeed, et al.
Publicado: (2020)

Performance of multi-parametric magnetic resonance imaging through PIRADS scoring system in biopsy naïve patients with suspicious prostate cancer
por: Nowier, Amr, et al.
Publicado: (2022)

Pushing the boundaries: emerging role of radical prostatectomy as part of multimodal treatment for oligometastatic prostate cancer
por: Sosnowski, Roman, et al.
Publicado: (2023)

Small lymphocytic lymphoma of the prostate mimicking a PIRADS 5 lesion that resolved after systemic treatment
por: Wong, Tiffany H., et al.
Publicado: (2021)

Poor reproducibility of PIRADS score in two multiparametric MRIs before biopsy in men with elevated PSA
por: Müller, Stig, et al.
Publicado: (2018)

Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime?
por: Poletajew, Sławomir, et al.
Publicado: (2020)

A Novel Nomogram Combined the Aggregate Index of Systemic Inflammation and PIRADS Score to Predict the Risk of Clinically Significant Prostate Cancer
por: Xie, Wenliang, et al.
Publicado: (2023)

The impact of a second MRI and re-biopsy in patients with initial negative mpMRI-targeted and systematic biopsy for PIRADS ≥ 3 lesions
por: Zattoni, Fabio, et al.
Publicado: (2023)

Prostate Imaging Reporting and Data System in prostate cancer staging and planning for radical prostatectomy
por: Kozikowski, Mieszko, et al.
Publicado: (2019)

Maintaining physical activity in the era of COVID-19 pandemic: a chair-based exercise program for home-isolated elderly prostate cancer patients
por: Pańczyk, Joanna, et al.
Publicado: (2020)

TGF-β and microRNA Interplay in Genitourinary Cancers
por: Boguslawska, Joanna, et al.
Publicado: (2019)

Active surveillance for low-risk prostate cancer – in pursuit of a standardized protocol
por: Sosnowski, Roman, et al.
Publicado: (2020)

Non-Invasive Biomarkers in the Diagnosis of Upper Urinary Tract Urothelial Carcinoma—A Systematic Review
por: Białek, Łukasz, et al.
Publicado: (2022)

Human kidney injury molecule-1 as a urine biomarker differentiating urothelial and renal cell carcinoma
por: Białek, Łukasz, et al.
Publicado: (2021)

piRNAs and PIWI Proteins as Diagnostic and Prognostic Markers of Genitourinary Cancers
por: Hanusek, Karolina, et al.
Publicado: (2022)

Temporal changes of PIRADS scoring by radiologists and correlation to radical prostatectomy pathological outcomes
por: Hong, Sung Kyu, et al.
Publicado: (2022)

Surveillance one year post focal cryotherapy for clinically significant prostate cancer using mpMRI and PIRADS v2.1: An initial experience from a prospective phase II mandatory biopsy study
por: Velaga, Jyothirmayi, et al.
Publicado: (2023)

A prospective, randomized trial comparing the use of KTP (GreenLight) laser versus electroresection-supplemented laser in the treatment of benign prostatic hyperplasia
por: Torz, Cezary, et al.
Publicado: (2016)

Bladder perforation during transurethral resection of bladder tumour is not a result of a deficient structure of the bladder wall
por: Poletajew, Sławomir, et al.
Publicado: (2020)

Catheter-associated bacterial flora in patients with benign prostatic hyperplasia: shift in antimicrobial susceptibility pattern
por: Dybowski, Bartosz A., et al.
Publicado: (2018)

The impact of coronavirus disease 2019 (COVID-19) pandemic on urologic cancer care: did we throw the baby out with the bathwater?
por: Kamecki, Hubert, et al.
Publicado: (2023)

Magnetic Resonance Imaging–targeted Prostate Biopsy Compared with Systematic Prostate Biopsy in Biopsy-naïve Patients with Suspected Prostate Cancer
por: Alkema, Nicolette G., et al.
Publicado: (2022)

The use of prostate MR for targeting prostate biopsies
por: Kelley, R. Phelps, et al.
Publicado: (2019)

Biopsy interpretation of the prostate
por: Epstein, Jonathan I.

Prostate biopsy interpretation
por: Epstein, Jonathan I.

Clinical analysis of EV‐Fingerprint to predict grade group 3 and above prostate cancer and avoid prostate biopsy
por: Fairey, Adrian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a57m1l1rl64n2a7bqm6qmrucnv